WO2002089796A3 - Methods for selective immunomodulation using pimecrolimus - Google Patents

Methods for selective immunomodulation using pimecrolimus Download PDF

Info

Publication number
WO2002089796A3
WO2002089796A3 PCT/US2002/014637 US0214637W WO02089796A3 WO 2002089796 A3 WO2002089796 A3 WO 2002089796A3 US 0214637 W US0214637 W US 0214637W WO 02089796 A3 WO02089796 A3 WO 02089796A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pimecrolimus
immunomodulation
selective
epithelial
Prior art date
Application number
PCT/US2002/014637
Other languages
French (fr)
Other versions
WO2002089796A2 (en
Inventor
Salah-Dine Chibout
Andre Cordier
Jeanne Kehren
Henrietta Denise Moore
Original Assignee
Novartis Ag
Salah-Dine Chibout
Andre Cordier
Jeanne Kehren
Henrietta Denise Moore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Salah-Dine Chibout, Andre Cordier, Jeanne Kehren, Henrietta Denise Moore filed Critical Novartis Ag
Priority to BR0209474-6A priority Critical patent/BR0209474A/en
Priority to JP2002586931A priority patent/JP2005512946A/en
Priority to AU2002256507A priority patent/AU2002256507A1/en
Priority to EP02725977A priority patent/EP1389108A2/en
Priority to CA002442969A priority patent/CA2442969A1/en
Publication of WO2002089796A2 publication Critical patent/WO2002089796A2/en
Publication of WO2002089796A3 publication Critical patent/WO2002089796A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to methods to produce selective immunomodulation in epithelial tissues to treat epithelial inflammatory disorders. This invention provides methods for the use of pimecrolimus to treat epithelial inflammatory disorders, including asthma and inflammatory bowel disease while minimizing systemic side effects.
PCT/US2002/014637 2001-05-09 2002-05-09 Methods for selective immunomodulation using pimecrolimus WO2002089796A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR0209474-6A BR0209474A (en) 2001-05-09 2002-05-09 Methods for Selective Immunomodulation
JP2002586931A JP2005512946A (en) 2001-05-09 2002-05-09 Selective immunomodulation method
AU2002256507A AU2002256507A1 (en) 2001-05-09 2002-05-09 Methods for selective immunomodulation using pimecrolimus
EP02725977A EP1389108A2 (en) 2001-05-09 2002-05-09 Methods for selective immunomodulation using pimecrolimus
CA002442969A CA2442969A1 (en) 2001-05-09 2002-05-09 Methods for selective immunomodulation using pimecrolimus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28984301P 2001-05-09 2001-05-09
US60/289,843 2001-05-09

Publications (2)

Publication Number Publication Date
WO2002089796A2 WO2002089796A2 (en) 2002-11-14
WO2002089796A3 true WO2002089796A3 (en) 2003-03-13

Family

ID=23113348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014637 WO2002089796A2 (en) 2001-05-09 2002-05-09 Methods for selective immunomodulation using pimecrolimus

Country Status (8)

Country Link
US (1) US20030119797A1 (en)
EP (1) EP1389108A2 (en)
JP (1) JP2005512946A (en)
CN (1) CN1543345A (en)
AU (1) AU2002256507A1 (en)
BR (1) BR0209474A (en)
CA (1) CA2442969A1 (en)
WO (1) WO2002089796A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
NZ539850A (en) * 2002-11-15 2008-05-30 Novartis Ag Drug delivery device or system comprising pimecromilus
AR043504A1 (en) * 2003-03-17 2005-08-03 Novartis Ag PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307862D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
CN1890384A (en) * 2003-10-06 2007-01-03 诺瓦提斯公司 Use of genetic polymorphisms associated with therapeutic efficacy of inflammatory diseases
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
GB0505539D0 (en) * 2005-03-17 2005-04-27 Novartis Ag Organic compounds
CN101166534B (en) * 2005-04-28 2011-09-21 大日本住友制药株式会社 Therapeutic agent for chronic obstructive pulmonary disease
BRPI0812729A2 (en) * 2007-06-13 2019-02-12 Pravda Jay Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
CA2891090A1 (en) 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006649A1 (en) * 1993-09-01 1995-03-09 Sandoz Ltd. Macrolides as antagonists of macrophilin binding immunosuppressants
WO1996031514A1 (en) * 1995-04-06 1996-10-10 Novartis Ag Ascomycins
US6004973A (en) * 1995-07-14 1999-12-21 Novartis Ag Pharmaceutical compositions comprising rafamycin coprecipitates
EP1064942A1 (en) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
WO2001026605A2 (en) * 1999-10-11 2001-04-19 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor
WO2001090110A1 (en) * 2000-05-22 2001-11-29 Novartis Ag Macrolides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006649A1 (en) * 1993-09-01 1995-03-09 Sandoz Ltd. Macrolides as antagonists of macrophilin binding immunosuppressants
WO1996031514A1 (en) * 1995-04-06 1996-10-10 Novartis Ag Ascomycins
US6004973A (en) * 1995-07-14 1999-12-21 Novartis Ag Pharmaceutical compositions comprising rafamycin coprecipitates
EP1064942A1 (en) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
WO2001026605A2 (en) * 1999-10-11 2001-04-19 Fujisawa Pharmaceutical Co., Ltd. Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor
WO2001090110A1 (en) * 2000-05-22 2001-11-29 Novartis Ag Macrolides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Dorland's illustrated medical dictionary - Edition 24", 1967, W.B. SAUNDERS COMPANY, PHILADELPHIA AND LONDON, XP002219801 *
HARPER J ET AL: "First experience of topical SDZ ASM 981 in children with atopic dermatitis.", BRITISH JOURNAL OF DERMATOLOGY, vol. 144, no. 4, April 2001 (2001-04-01), pages 781 - 787, XP008008795, ISSN: 0007-0963 *
RAPPERSBERGER K ET AL: "Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 114, no. 4, April 2000 (2000-04-01), 61st Annual Meeting of the Society for Investigative Dermatology.;Chicago, Illinois, USA; May 10-14, 2000, pages 776, XP008008802, ISSN: 0022-202X *
See also references of EP1389108A2 *
WELLINGTON KERI ET AL: "SDZ ASM 981.", BIODRUGS, vol. 14, no. 6, December 2000 (2000-12-01), pages 409 - 416, XP008008793, ISSN: 1173-8804 *

Also Published As

Publication number Publication date
EP1389108A2 (en) 2004-02-18
BR0209474A (en) 2006-02-07
US20030119797A1 (en) 2003-06-26
AU2002256507A1 (en) 2002-11-18
CN1543345A (en) 2004-11-03
JP2005512946A (en) 2005-05-12
WO2002089796A2 (en) 2002-11-14
CA2442969A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2002089796A3 (en) Methods for selective immunomodulation using pimecrolimus
AU2009201956A2 (en) Pregnane steroids for use in the treatment of CNS disorders
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2002363190A1 (en) Compositions and methods for prostate and kidney health and disorders, an herbal preparation
AU2002224417A1 (en) Methods for treating il-18 mediated disorders
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2004071382A3 (en) Substituted heterocycles
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
PL368045A1 (en) Combinations for the treatment of inflammatory disorders
SI1446122T1 (en) Use of flibanserin in the treatment of sexual desire disorders
EP1450837A4 (en) Interleukin-1 receptors in the treatment of diseases
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
IL175610A0 (en) Methods and reagents for the treatment of inflammatory disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
EP1478438A4 (en) Methods and compositions for the treatment of asthma and related disorders
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2003298913A1 (en) Treatment of inflammatory disorders with 2,3-benzodiazepines
ZA200505989B (en) Use the steroids to treat ocular disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002725977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2442969

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002586931

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028095200

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002725977

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: PI0209474

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2002725977

Country of ref document: EP